Metagla (Methadone Hydrochloride)

Methadone works mainly as a full agonist at the µ‑opioid receptor, delivering analgesia and suppressing withdrawal. It also blocks NMDA receptors and inhibits reuptake of serotonin and norepinephrine, which adds benefit for neuropathic pain and helps limit the development of opioid tolerance.

The dose of Metagla is individualized. A qualified prescriber determines the appropriate starting amount, titration schedule, and maintenance dose based on the patient’s clinical condition, prior opioid exposure, and response to therapy. No fixed dosing regimen is provided in public information.

Methadone’s pregnancy category is listed as unknown. Use during pregnancy or lactation should only occur when the potential benefit justifies potential risk to the fetus or infant. Clinicians must weigh the need for opioid dependence treatment against possible adverse effects and discuss options with the patient.

To request Metagla, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with buprenorphine, another opioid‑maintenance option, methadone provides a longer half‑life and full µ‑receptor agonism, which can result in more stable plasma levels but also a higher risk of respiratory depression. Buprenorphine has a ceiling effect for respiratory depression, making it safer in some settings, while methadone may be preferred for patients needing stronger analgesia.

Metagla should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in areas with extreme heat or humidity to maintain potency.

Metagla is taken orally. The tablet (or other oral form) should be swallowed whole with water and not chewed, crushed, or dissolved unless specifically instructed by a healthcare professional. Dosing times are usually once daily, but the prescriber may adjust frequency based on individual response.

The most critical risks include respiratory depression, especially after dose increases or when combined with other CNS depressants, QT‑interval prolongation that can lead to arrhythmias, and severe hypotension. Patients should be educated to seek immediate medical attention if they experience shallow breathing, fainting, palpitations, or sudden drops in blood pressure.

Metagla is contraindicated in individuals with known hypersensitivity to methadone or any component of the formulation, in patients with severe respiratory insufficiency, acute asthma, or uncontrolled severe constipation. Caution is also advised for those taking MAO inhibitors, and it should be avoided in patients with significant cardiac conduction abnormalities that predispose to QT prolongation.